Inhibition of LpxC increases antibiotic susceptibility in Acinetobacter baumannii

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 8, 2016, Pages 5076-5079

  García Quintanilla, Meritxell ^a   Caro Vega, José M ^a   Pulido, Marina R ^a   Moreno Martínez, Patricia ^a   Pachón, Jerónimo ^a   McConnell, Michael J ^a  

^a CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZITHROMYCIN; BACTERIUM LIPOPOLYSACCHARIDE; CIPROFLOXACIN; DRUG; ENDOTOXIN; IMIPENEM; LIPID A; LPXC; PF 5081090; RIFAMPICIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN; AMIDASE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; CARBAPENEM DERIVATIVE; MINOCYCLINE;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL; BACTERICIDAL ACTIVITY; CELL MEMBRANE PERMEABILITY; COLONY FORMING UNIT; GENE MUTATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; ACINETOBACTER INFECTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AMIDOHYDROLASES; AMIKACIN; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BACTERIAL PROTEINS; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; IMIPENEM; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; RIFAMPIN; VANCOMYCIN;

EID: 84979284304     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00407-16     Document Type: Article

References (17)

1. McConnell MJ, Actis L, Pachon J. 2013. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol Rev 37:130-155. http://dx.doi.org/10.1111/j.1574-6976.2012.00344.x.
2. Barb AW, Zhou P. 2008. Mechanism and inhibition of LpxC: an essential zinc-dependent deacetylase of bacterial lipid A synthesis. Curr Pharm Biotechnol 9:9-15. http://dx.doi.org/10.2174/138920108783497668.
3. Tomaras AP, McPherson CJ, Kuhn M, Carifa A, Mullins L, George D, Desbonnet C, Eidem TM, Montgomery JI, Brown MF, Reilly U, Miller AA, O'Donnell JP. 2014. LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid A biosynthesis in Gram-negative pathogens. mBio 5(5):e01551-14. http://dx.doi.org/10.1128/mBio.01551-14.
4. Actis LA, Tolmasky ME, Crosa LM, Crosa JH. 1993. Effect of ironlimiting conditions on growth of clinical isolates of Acinetobacter baumannii. J Clin Microbiol 31:2812-2815.
5. Brown MF, Reilly U, Abramite JA, Arcari JT, Oliver R, Barham RA, Che Y, Chen JM, Collantes EM, Chung SW, Desbonnet C, Doty J, Doroski M, Engtrakul JJ, Harris TM, Huband M, Knafels JD, Leach KL, Liu S, Marfat A, Marra A, McElroy E, Melnick M, Menard CA, Montgomery JI, Mullins L, Noe MC, O'Donnell J, Penzien J, Plummer MS, Price LM, Shanmugasundaram V, Thoma C, Uccello DP, Warmus JS, Wishka DG. 2012. Potent inhibitors of LpxC for the treatment of Gram-negative infections. J Med Chem 55:914-923. http://dx.doi.org/10.1021/jm2014748.
6. Montgomery JI, Brown MF, Reilly U, Price LM, Abramite JA, Arcari J, Barham R, Che Y, Chen JM, Chung SW, Collantes EM, Desbonnet C, Doroski M, Doty J, Engtrakul JJ, Harris TM, Huband M, Knafels JD, Leach KL, Liu S, Marfat A, McAllister L, McElroy E, Menard CA, Mitton-Fry M, Mullins L, Noe MC, O'Donnell J, Oliver R, Penzien J, Plummer M, Shanmugasundaram V, Thoma C, Tomaras AP, Uccello DP, Vaz A, Wishka DG. 2012. Pyridone methylsulfone hydroxamate LpxC inhibitors for the treatment of serious Gram-negative infections. J Med Chem 55:1662-1670. http://dx.doi.org/10.1021/jm2014875.
7. Lin L, Tan B, Pantapalangkoor P, Ho T, Baquir B, Tomaras A, Montgomery JI, Reilly U, Barbacci EG, Hujer K, Bonomo RA, Fernandez L, Hancock RE, Adams MD, French SW, Buslon VS, Spellberg B. 2012. Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. mBio 3(5):e00312-12. http://dx.doi.org/10.1128/mBio.00312-12.
8. Moffatt JH, Harper M, Adler B, Nation RL, Li J, Boyce JD. 2011. Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. Antimicrob Agents Chemother 55:3022-3024. http://dx.doi.org/10.1128/AAC.01732-10.
9. Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, Henry R, Crane B, St Michael F, Cox AD, Adler B, Nation RL, Li J, Boyce JD. 2010. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 54:4971-4977. http://dx.doi.org/10.1128/AAC.00834-10.
10. García-Quintanilla M, Carretero-Ledesma M, Moreno-Martinez P, Martin-Pena R, Pachon J, McConnell MJ. 2015. Lipopolysaccharide loss produces partial colistin dependence and collateral sensitivity to azithromycin, rifampicin and vancomycin in Acinetobacter baumannii. Int J Antimicrob Agents 46:696-702. http://dx.doi.org/10.1016/j.ijantimicag.2015.07.017.
11. Fernández -Cuenca F, Tomas-Carmona M, Caballero-Moyano F, Bou G, Martinez-Martinez L, Vila J, Pachon J, Cisneros JM, Rodriguez-Bano J, Pascual A. 2013. In vitro activity of 18 antimicrobial agents against clinical isolates of Acinetobacter spp.: multicenter national study GEIH-REIPI-Ab 2010. Enferm Infecc Microbiol Clin 31:4-9. (In Spanish.) http://dx.doi.org/10.1016/j.eimc.2012.06.010.
12. García-Quintanilla M, Pulido MR, Moreno-Martinez P, Martin-Pena R, Lopez-Rojas R, Pachon J, McConnell MJ. 2014. Activity of host antimicrobials against multidrug-resistant Acinetobacter baumannii acquiring colistin resistance through loss of lipopolysaccharide. Antimicrob Agents Chemother 58:2972-2975. http://dx.doi.org/10.1128/AAC.02642-13.
13. García-Quintanilla M, Pulido MR, Pachon J, McConnell MJ. 2014. Immunization with lipopolysaccharide-deficient whole cells provides protective immunity in an experimental mouse model of Acinetobacter baumannii infection. PLoS One 9:e114410. http://dx.doi.org/10.1371/journal.pone.0114410.
14. Drago L, De Vecchi E, Nicola L, Gismondo MR. 2007. In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections. BMC Infect Dis 7:111. http://dx.doi.org/10.1186/1471-2334-7-111.
15. Buendía-Clavería AM, Moussaid A, Ollero FJ, Vinardell JM, Torres A, Moreno J, Gil-Serrano AM, Rodriguez-Carvajal MA, Tejero-Mateo P, Peart JL, Brewin NJ, Ruiz-Sainz JE. 2003. A purL mutant of Sinorhizobium fredii HH103 is symbiotically defective and altered in its lipopolysaccharide. Microbiology 149:1807-1818. http://dx.doi.org/10.1099/mic.0.26099-0.
16. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - 9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
17. Gordon NC, Png K, Wareham DW. 2010. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 54:5316-5322. http://dx.doi.org/10.1128/AAC.00922-10.